

Oncoceutics Announces Support for All Those Affected by Gliomas on Glioblastoma Awareness Day

20 July 2019 | News

In this particularly devastating disease, there is still a significant unmet medical need that remains to be addressed by therapies that are under development.



Philadelphia, PA (July 17, 2019) -

Oncoceutics, Inc. issues this announcement on Glioblastoma Awareness Day to reiterate its support for all those suffering from, or broadly affected by, gliomas. A bipartisan resolution, <u>Senate Resolution 245</u>, introduced on May 16, 2019, by U.S. Senator Lindsey Graham (R-SC), with the support of Senators Mitch McConnell (R-KY), Elizabeth Warren (D-MA), Kyrsten Sinema (D-AZ), and Martha McSally (R-AZ), designated today, July 17th 2019 as National Glioblastoma Awareness Day.

"We ask America to join us in reflection on this July 17 Glioblastoma Awareness Day" said Wolfgang Oster, MD, PhD, and Chief Executive Officer of Oncoceutics. "We must continue to support those who suffer from gliomas, whether as patients, friends, or family, as we advance research to hopefully, one day, cure this disease."

Oncoceutics continues to focus its developmental work on brain tumors with a specific type of genetic mutation called H3 K27M-mutant glioma. This mutation is present in approximately 10% of all gliomas, and occurs at a particularly high rate among children and young adults. Emerging results from clinical trials with the company's lead compound ONC201 in patients with H3 K27M-mutant glioma, appear to be highly encouraging as represented by the FDA's invitation to the company to present at the pediatric Oncology Drug Advisory Committee. This meeting was held on June 20 and alink is available to view the full event.